Xin Lang Cai Jing·2025-10-08 11:58Core Insights - The company reported a revenue of 1.1 billion yuan for H1 2025, a decrease of 9.97% year-on-year, while the net profit attributable to shareholders increased by 7.56% to 134 million yuan [1] - Cost reduction and efficiency improvement measures are showing positive results, with sales expenses down 31.28% to 294 million yuan and management expenses down 21.58% to 56.75 million yuan [2] - The company signed promotional agreements for Pemabate tablets, which are expected to enhance its product pipeline and competitiveness in the cardiovascular field [3] - Revenue forecasts for 2025-2027 have been adjusted to 2.364 billion, 2.464 billion, and 2.661 billion yuan, while net profit forecasts have been increased to 258 million, 282 million, and 318 million yuan [4] Financial Performance - H1 2025 revenue: 1.1 billion yuan, down 9.97% year-on-year [1] - H1 2025 net profit: 134 million yuan, up 7.56% year-on-year [1] - H1 2025 non-recurring net profit: 107 million yuan, up 13.28% year-on-year [1] Cost Management - Sales expenses decreased from 428 million yuan to 294 million yuan, a reduction of 31.28% [2] - Sales expense ratio fell from 35.06% in H1 2024 to 26.76% [2] - Management expenses decreased from 72.37 million yuan to 56.75 million yuan, a reduction of 21.58% [2] - Asset-liability ratio improved from 31.66% to 28.70% [2] Product Development - The company signed a joint promotion agreement for Pemabate tablets, which have a promising market outlook [3] - Pemabate tablets are the first new selective PPARα modulator approved in China, aimed at lowering triglyceride levels [3] - The promotion of Pemabate tablets is expected to enhance the company's revenue and profit, as well as its academic promotion capabilities [3] Revenue and Profit Forecast - Adjusted revenue forecasts for 2025-2027: 2.364 billion, 2.464 billion, and 2.661 billion yuan [4] - Adjusted net profit forecasts for 2025-2027: 258 million, 282 million, and 318 million yuan [4]